| Identification | Back Directory | [Name]
1-Butanone, 1-[4-(difluoromethoxy)-3-[(tetrahydro-3-furanyl)oxy]phenyl]-3-methyl- | [CAS]
1093412-18-0 | [Synonyms]
FFPM
Roflupram >=98% (HPLC)
1-Butanone, 1-[4-(difluoromethoxy)-3-[(tetrahydro-3-furanyl)oxy]phenyl]-3-methyl- | [Molecular Formula]
C16H20F2O4 | [MDL Number]
MFCD31697733 | [MOL File]
1093412-18-0.mol | [Molecular Weight]
314.32 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (318.15 mM; Need ultrasonic) | [form ]
Liquid | [color ]
Colorless to light yellow | [InChIKey]
IXURVUHDDXFYDR-UHFFFAOYSA-N | [SMILES]
O=C(CC(C)C)C1=CC=C(OC(F)F)C(OC2CCOC2)=C1 |
| Hazard Information | Back Directory | [Uses]
Roflupram is a selective, orally active and brain-penetrant PDE4 inhibitor, with an IC50 of 26.2 nM for core catalytic domains of human PDE4. Roflupram can reverse cognitive deficits and reduce the production of pro-inflammatory factors[1][2]. | [Biological Activity]
Roflupram is a selective, orally active and brain-penetrant PDE4 inhibitor, with an IC50 of 26.2 nM for core catalytic domains of human PDE4. Roflupram can reverse cognitive deficits and reduce the production of pro-inflammatory factors[1][2]. | [IC 50]
PDE4: 26.2 nM (IC50) | [References]
[1]. Li D, et, al. Roflupram, a novel phosphodiesterase 4 inhibitor, inhibits lipopolysaccharide-induced neuroinflammatory responses through activation of the AMPK/Sirt1 pathway. Int Immunopharmacol. 2021 Jan;90:107176.
[2]. You T, et, al. Roflupram, a Phosphodiesterase 4 Inhibitior, Suppresses Inflammasome Activation through Autophagy in Microglial Cells. ACS Chem Neurosci. 2017 Nov 15;8(11):2381-2392. |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|